Go Deep
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 20,998 | 40.5 | 3.90 | 0.37 | 914.00 |
| Sep 2026 | 20,998 | 40.5 | 3.90 | 0.37 | 914.00 |
| Sep 2026 | 20,998 | 40.5 | 3.90 | 0.37 | 914.00 |
| Oct 2026 | 20,676 | 42.9 | 4.13 | 0.37 | 968.50 |
| Oct 2026 | 21,025 | 36.4 | 3.65 | 0.37 | 855.50 |
Aarti Pharmalabs Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 5,357,969,000.0 | 5,826,440,000.0 | 4,322,727,000.0 | 4,183,348,000.0 |
| Net Profit | 761,427,000.0 | 611,241,000.0 | 479,556,000.0 | 279,231,000.0 |
| EPS | 8.4 | 6.7 | 5.3 | 3.1 |
Aarti Pharmalabs Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 17,877,676,000.0 | 20,860,021,000.0 | 18,155,052,000.0 | 19,360,045,000.0 | — |
| Net Profit | 1,747,073,000.0 | 2,724,048,000.0 | 2,169,021,000.0 | 1,934,934,000.0 | — |
| EPS | 19.3 | 30.1 | 23.9 | 21.4 | — |
Aarti Pharmalabs Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 34,817,059,000.0 | 29,024,295,000.0 | 25,821,051,000.0 | 22,440,238,000.0 | — |
| Total Liabilities | 13,571,013,000.0 | 9,125,231,000.0 | 8,250,659,000.0 | 6,855,372,000.0 | — |
| Total Equity | 21,246,046,000.0 | 19,899,064,000.0 | 17,570,392,000.0 | 15,584,866,000.0 | — |
Owes vs Owns
Aarti Pharmalabs Limited owed ₹0.39 for every ₹1 it owned in Mar 2026, up from ₹0.31 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.39× | 0.31× | 0.32× | 0.31× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aarti Pharmalabs Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Receivables 16.8%Inventory 18.4%Fixed assets (tangible) 49.5%Intangible assets 3.6%Long-term investments 4.8%Other assets 6.7%
How it's funded — Mar 2026
Short-term debt 14.4%Long-term debt 5.8%Payables 9.6%Other liabilities 9.2%Shareholders' equity 61.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 8.9 | 51.6 | 94.0 | 63.1 |
| Receivables | 583.3 | 575.4 | 519.3 | 450.1 |
| Inventory | 640.3 | 587.6 | 642.9 | 602.0 |
| Fixed assets (tangible) | 1,723.5 | 1,433.4 | 1,105.4 | 988.6 |
| Intangible assets | 123.9 | 100.2 | 77.1 | 41.6 |
| Long-term investments | 167.7 | 5.7 | 5.7 | 5.7 |
| Other assets | 234.1 | 148.5 | 137.7 | 92.9 |
| Liabilities & equity | ||||
| Short-term debt | 499.8 | 292.8 | 264.1 | 214.2 |
| Long-term debt | 200.8 | 111.3 | 0.0 | 0.2 |
| Payables | 334.5 | 277.8 | 378.3 | 339.5 |
| Other liabilities | 321.9 | 230.6 | 182.6 | 131.7 |
| Shareholders' equity | 2,124.6 | 1,989.9 | 1,757.0 | 1,558.5 |
| Net tangible assets | 2,000.7 | 1,889.7 | 1,680.0 | 1,516.9 |
Aarti Pharmalabs Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 2,619,315,000.0 | 3,301,394,000.0 | 2,163,546,000.0 | 2,501,154,000.0 | — |
| Investing Activities | -4,307,171,000.0 | -4,124,754,000.0 | -2,145,644,000.0 | -1,578,030,000.0 | — |
| Financing Activities | 1,705,822,000.0 | 654,349,000.0 | 97,235,000.0 | -1,634,646,000.0 | — |